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Abstract
Background: Measles was responsible for an estimated 100,000 deaths worldwide in 2008. Despite being a
vaccine-preventable disease, measles remains a major cause of morbidity and mortality in young children.
Although a safe and effective injectable measles vaccine has been available for over 50 years it has not been
possible to achieve the uniformly high levels of coverage (required to achieve measles eradication) in most parts of
the developing world. Aerosolised measles vaccines are now under development with the hope of challenging the
delivery factors currently limiting the coverage of the existing vaccine.
Methods: We used a modified CHNRI methodology for setting priorities in health research investments to assess
the strengths and weaknesses of this emerging intervention to decrease the burden of childhood pneumonia. This
was done in two stages. In Stage I, we systematically reviewed the literature related to emerging aerosol vaccines
against measles relevant to several criteria of interest. Although there are a number of different aerosol vaccine
approaches under development, for the purpose of this exercise, all were considered as one intervention. The
criteria of interest were: answerability; cost of development, production and implementation; efficacy and
effectiveness; deliverability, affordability and sustainability; maximum potential impact on disease burden reduction;
acceptability to the end users and health workers; and effect on equity. In Stage II, we conducted an expert
opinion exercise by inviting 20 experts (leading basic scientists, international public health researchers, international
policy makers and representatives of pharmaceutical companies). The policy makers and industry representatives
accepted our invitation on the condition of anonymity, due to the sensitive nature of their involvement in such
exercises. They answered questions from the CHNRI framework and their “collective optimism” towards each
criterion was documented on a scale from 0 to 100%.
Results: The panel of experts expressed mixed feelings about an aerosol measles vaccine. The group expressed
low levels of optimism regarding the criteria of likelihood of efficacy and low cost of development (scores around
50%); moderate levels of optimism regarding answerability, low cost of production, low cost of implementation
and affordability (score around 60%); and high levels of optimism regarding deliverability, impact on equity and
acceptability to health workers and end-users (scores over 80%). Finally, the experts felt that this intervention will
have a modest but nevertheless important impact on reduction of burden of disease due to childhood pneumonia
(median: 5%, interquartile range 1-15%, minimum 0%, maximum 45%).
Conclusion: Aerosol measles vaccine is at an advanced stage of development, with evidence of good
immunogenicity. This new intervention will be presented as a feasible candidate strategy in the campaign for
global elimination of measles. It also presents an unique opportunity to decrease the overall burden of disease due
to severe pneumonia in young children.
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Despite the availability of an effective vaccine, the global
burden of disease due to measles continues to be high
in young children. Although the coverage of the first
dose of measles vaccine improved dramatically in the
twenty first century, it is estimated that in the year 2008
approximately 100,000 deaths in children aged less than
5 years was attributable to measles [1,2]. Failure to
achieve universal coverage for at least one dose of
measles vaccine remains the key reason for these deaths.
Pneumonia is one of the most common fatal complica-
tions of measles [3]. In 2008, all World Health Organi-
zation (WHO) member states reaffirmed their
commitment to reduce the global measles mortality to
less than 75,000 deaths by 2010 (i.e. 90% reduction in
measles mortality compared to the year 2000) [4]. This
would in turn contribute to an overall reduction in bur-
den of disease due to childhood pneumonia.
The debate regarding the feasibility of achieving a
m e a s l e sf r e ew o r l dh a sb e e no n g o i n gf o rt h el a s tt w o
decades. The meeting of the International Task Force
for Disease Eradication in June 2009 evaluated the avail-
able evidence for the potential eradicability of measles
and concluded with greater confidence (than at the pre-
vious meeting in 2002) that “measles eradication is bio-
logically possible using available tools…Research to
discover new tools or to improve existing ones is needed
to strengthen the arsenal against this contagious disease.
Any practical breakthrough in ways to mitigate any of
the current requirements to inject, provide 2 doses,
refrigerate measles vaccine, and to improve efficacy in
young infants, would be a major contribution to measles
eradication” [5]. Two of the major components of the
comprehensive strategy for measles eradication were
achieving and maintaining high coverage (>90%) with
the routinely scheduled first dose of measles-containing
vaccine (MCV1) among children aged 1 year and to
ensure that all children receive a second opportunity for
measles immunization (either through a second routine
dose or through periodic supplementary immunization
activities (SIAs)). However, to implement these strate-
gies in the field, a more simplified and effective delivery
method would need to be developed.
The injectable measles vaccine received its licensure in
1963 and since then worldwide vaccination programmes
have been employed in an attempt to control the disease
[6]. The existing vaccine has proved extremely efficacious
in the prevention of the disease. Between 2000 and 2007
global measles mortality declined by 74 percent with a 10
percent overall increase in vaccine coverage (estimated
worldwide coverage of the first dose of measles vaccine
in 2007 was approximately 82 percent) [1]. However, this
coverage is not uniform- there are wide disparities in
coverage among countries and pockets of poor coverage
remain within countries with overall coverage above 80
percent. In 2007, MCV1 coverage in WHO Africa and
South East Asia regions was 74% and 73% respectively [7]
– two regions particularly vulnerable to disease out-
breaks and which contribute to a substantial proportion
of the global disease burden of measles. WHO has identi-
fied 47 priority countries which account for the highest
percentage of measles deaths and have been made the
focus of a comprehensive strategy for a targeted disease
reduction [4]. As a result, researchers are exploring more
effective ways to achieve universal coverage of measles
vaccine amongst the poorer sections of the society in low
and middle income countries. One of the strategies
under consideration to improve delivery of the existing
measles vaccine is needle free administration of the vac-
cine. Such a delivery mechanism could help achieve uni-
versal coverage of the vaccine in the hard to reach areas
in resource poor settings [8].
In 1983, Albert Sabin described his vision of creating
an aerosolized measles vaccine [9]. His concept was to
create a vaccine that was simple, safe, cost-efficient and
could be easily implemented into mass vaccination cam-
paigns. The initial vaccine developed by him was piloted
in Mexico and data from the limited serological and
field studies demonstrated the safety and immunogeni-
city of the vaccine in infants and children [10]. Follow-
ing this, more than 4 million children throughout
Mexico were vaccinated against measles using the aero-
sol route of administration during mass campaigns [11].
However, the success was limited as the aerosol vaccine
(effective in children aged 1 year and above) was never
tested or incoporated into routine immunization pro-
grammes. In 2002 the Measles Aerosol Project (MAP)
was established to develop at least one method for
respiratory delivery of currently licensed measles vac-
cines [12]. In addition to MAP, there are a number of
other research efforts to develop and evaluate an aerosol
measles vaccine.
We aimed to review the existing literature, outlining
the progress of the emerging aerosol measles vaccines at
all stages of development; present the evidence regarding
key issues surrounding aerosolized measles vaccine and
assess the level of collective optimism of international
experts over its priority status for receiving investment
support as a strategy to decrease pneumonia burden in
children. The paper is presented as part of a series of
papers, each in turn focusing on different emerging vac-
cines and other interventions against pneumonia.
Methods
We used a modified Child Health and Nutrition
Research Initiative (CHNRI) methodology for setting
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ogy has been described in great detail [13-17] and
implemented in a variety of settings [18-23]. Briefly, the
method uses a set of pre-defined criteria and collects
expert opinion of all stakeholders on the risks and bene-
fits associated with investing in existing and / or new
interventions.
CHNRI exercise – stage I: Identification and selection of
studies
We applied the CHNRI method to estimate the poten-
tial impact of the aerosolized measles vaccines. We con-
ducted a systematic literature review using the following
criteria: answerability, cost of development, cost of pro-
duct, cost of implementation, efficacy and effectiveness,
deliverability, affordability, sustainability, maximum
potential impact on disease burden reduction, accept-
ability to health workers, acceptability to end users and
equity [13] (Figure 1). Details about the search strategies
are presented in Supplementary table 1 in Additional
file 1. The search was limited to Ovid MEDLINE,
Embase, Global Health, Web of Science, LILACS,
IndMed, and grey literature (SIGLE) databases from Jan-
uary 1994 to May 2009. (Although we updated the
search in January 2011, for Stage II of this exercise, the
experts were presented only with a summary of the lit-
erature from 1994 to May 2009). No language or publi-
cation restrictions were applied. In order to ensure
completeness, we also conducted hand searching of
online journals, scanned the reference list of identified
citations, and perused literature available on the web-
sites of pharmaceutical companies and international
agencies (GAVI and WHO).
We used a pre-determined eligibility criteria for
screening and including identified studies. In particular,
we included studies on aerosolized measles vaccine
derived from either Edmonston-Zagreb or Schwarz vac-
cine virus strains in children aged less than15 years;stu-
dies assessing other novel interventions against measles;
and studies addressing questions on answerability, effec-
tiveness, deliverability, disease burden reduction or
equity. We excluded studies reporting existing measles
interventions; use of measles vaccine in the adult popu-
lation; and not directly challenging the impact of
vaccines.
CHNRI exercise – stage II
We shared the initial review of the literature with 20
experts. The list of chosen experts included five leading
basic scientists, five international public health research-
ers, five international policy makers and five representa-
tives of the pharmaceutical companies. The 20 experts
were chosen based on their excellent track record in
child health research (but were not specifically involved
with measles disease research). We initially offered parti-
cipation to the 20 experts with the greatest impact of
publications in their area of expertise over the past 5
years (for basic researchers and international public
health researchers), or for being affiliated to the largest
pharmaceutical company in terms of vaccination pro-
gramme or international agency in terms of their annual
budget. For those who declined to participate (about
20%) replacements were found using the same criteria.
The policy makers and industry representatives accepted
our invitation on the condition of anonymity, due to
sensitive nature of their involvement in such exercises.
About half of the experts were either affiliated to insti-
tutions in developing countries or had previous experi-
ence of working in developing country settings. The
experts met during September 7-13, 2009 in Dubrovnik,
Croatia, to conduct the 2
nd stage of CHNRI expert opi-
nion exercise. The process of second-stage CHNRI is
shown in Figure 2. All invited experts discussed the evi-
dence provided in CHNRI stage I, and then answered
questions from CHNRI framework (see Supplementary
table 2 in Additional file 1). Their answers could have
been “Yes” (1 point), “No” (0 points), “Neither Yes nor
No” (0.5 points) or “Don’tk n o w ” (blank). Their “collec-
tive optimism” towards each criterion was documented
on a scale from 0 to 100%. The interpretation of this
metric for each criterion is simple: it is calculated as the
number of points that each evaluated type of emerging
aerosolized measles vaccine received from 20 experts
(based on their responses to questions from CHNRI fra-
mework), divided by the maximum possible number of
points (if all answers from all experts are “Yes”) [13-17].
Results
We identified 51 articles andp r o d u c tm o n o g r a p h sf o r
inclusion in the study. Currently several products are in
development phase, some of which have completed
phase I and II clinical trials.
Answerabilty
We evaluated the likelihood of an effective aerosolised
measles vaccine being available for incorporation into
the routine Expanded Programme of Immunization
(EPI) schedule or supplementary immunization cam-
paigns within in a time frame of 10 years. The potential
for measles aerosol vaccination has been recognized
since the 1960’s when American and Japanese research-
ers acknowledged a consistent immunogenic response in
children exposed to small amounts of aerosolized, partly
attenuated measles vaccine [9]. Measles is an airborne
disease, with transmission of the measles virus across
the respiratory mucosa. Delivery of measles vaccination
using aerosol technology aims to imitate this natural
pattern of infection [24]. It is assumed that aerosol
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criteria). CHNRI- Child Health and Nutrition Research Initiative.
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respiratory mucosa as well as systemically. In Eastern
Europe thousands of people have been immunized via
the respiratory mucosa, with live attenuated vaccine
against many infectious agents including anthrax and
small-pox [25].
One of the formulations of the aerosolized measles
vaccine proposes to use the same formulation as the
existing subcutaneous measles vaccine i.e. aerosolize the
liquid formulation of the current injectable vaccine. By
adopting this strategy, MAP has managed to avoid years
of investigations in attempting to reformulate the vac-
cine constitution [26]. Consequently, the development
process is limited to creating an innovative device which
can deliver the vaccine in a way that elicits an antibody
response of equivalent or greater immunogenicity to
that of the current vaccine.
Research efforts are also underway to produce an
inhalable dry powder vaccine. In one of these formula-
tions, the weakened measles virus will be mixed with
high-pressure carbon dioxide to produce microscopic
bubbles and droplets, which will then be gently dried to
produce an inhalable powder [27].
The existing vaccine product is a viable selection for
application to the aerosol device as it has a high success
rate of provoking good seroresponse. Over ninety five
Figure 2 A summary of Stage II of the CHNRI process of evaluation of an emerging intervention (an expert opinion exercise using the
CHNRI criteria). CHNRI- Child Health and Nutrition Research Initiative
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measles vaccine was given at 9 months, and over 99 per-
cent seroconvert if the first dose was given at or after 12
months [5]. The question is whether this response is
transferable to an aerosolized delivery system.
Two methods for the delivery of liquid aerosol vac-
cines are currently under trial. The inflatable bag aerosol
method, a concept introduced in 2009, has only com-
pleted proof of principle trials and has not yet entered
pre-clinical trials. The nebulized aerosol method has
completed phase I clinical trials and will shortly be
entering phase II/III clinical trials.
Robert Sievers and colleagues who have invented and
patented a device known as Carbon dioxoide Assisted
Nebuilization with a Bubble Dryer (CAN-BD) in a pre-
sentation at the 238th National Meeting of the Ameri-
can Chemical Society (ACS) indicated that the dry
powder measles vaccine (developed in collaboration
with Serum Institute of India) will be ready for entry
into phase I clinical trials in India in 2010 [27]. They
have also developed a dry powder live attenuated
measles vaccine which does not require reconstitution
and have demonstrated the safety and efficacy of the
vaccine in rhesus macaques [28].
Presented with these evidence, the panel of experts
however expressed moderate levels of optimism (score
around 60%) concerning the ability of aerosolized
measles to satisfy the criterion of answerability (Figure 3).
Efficacy and effectiveness
Liquid aerosolized measles vaccination has been evalu-
ated in a multitude of field studies dating back over the
last 30 years. The concept of an aerosolized vaccine was
proven to be feasible in very early clinical trials carried
out by Sabin et al. [29,30]. Following the results of these
trials, several research groups, predominantly in Mexico
and South Africa, pursued further research into measles
aerosol vaccination. Results of major clinical and pre-
clinical trials are outlined in Table 1 and Table 2
respectively.
Low and colleagues in a meta-analysis of results from
7 randomized trials, 4 non randomized trials, and 6
uncontrolled studies demonstrated that in the case of
children aged below 10 months, subcutaneous measles
vaccine showed a greater seroconversion rate compared
t ot h o s eu s i n gt h ea e r o s o lr o u t e[ 2 4 ] .T h e ys u g g e s t e d
that this was perhaps partly due to persistent maternal
antibodies (at this age) that interfered with the immune
response and partly due to the poor suitability of the
aerosol device for this age group. However, in children
aged 10 months and older, aerosolized measles vaccine
was found to be more immunogenic than the subcuta-
neous one. An earlier systematic review and meta-analy-
sis by Hiremath and Omer in 2005 using data from 20
results from 16 studies concluded that the measles vac-
cine administered via respiratory route is as at least as
immunogenic as subcutaneous vaccine [31]. Questions
however remain regarding the optimal age for the first
dose of the vaccine in high burden areas and the opti-
mal number of doses required to achieve a sero-conver-
sion rate above 95 percent in the population.
The nebulised aerosol measles vaccination entered
stage I clinical trials in India in 2006. There, 60 subjects
were assessed for their immunological responses at 3
different sites. The trial was due for completion in 2008,
but no results have yet been published. Preliminary data
suggest a low adverse event profile and good provoca-
tion of immunogenecity. Late stage clinical trials were
due to commence in 2007, but at present there are no
published data to ascertain the progress of the vaccine
(Figure 4).
Ar e c e n t“p r o o fo fp r i n c i p l e ” trial has been completed
using inflatable bag and valved mask technology. The
bags with 3-4 litre capacity were inflated with 0.053 ml
of vaccine in roughly 4 seconds, and inhaled until total
collapse of the bag was seen. Data from this trial
demonstrated almost double the number of children
showing a 4-fold or 2-fold boosted antibody response
when vaccinated via the inflatable bag than by injection.
Though this model proposes to offer similar advantages
to the nebulised formulation, it should be able to deliver
a more measurable dose between individuals and hopes
to offer greater protection in infants (Figure 4).
The dry powder vaccination has had a more pro-
tracted course of development (Figure 5). Although the
limited studies on such formulation have all highlighted
the plausibility of a marketable dry powder product,
none of the published data through May 2009 showed a
specific in vivo demonstration of clinical safety and effi-
cacy (Table 3). Scientists in the United States have
recently demonstrated that respiratory delivery of a sin-
gle dose of dry powder live attenuated measles vaccine
in rhesus macaques is capable of inducing durable fully
protective immunity comparable to the injectable vac-
cine [28].
Presented with the evidence from the literature
through May 2009 (Table 3), the panel of experts
expressed concern (score around 50%) regarding the
ability of aerosolized measles vaccines to satisfy the cri-
terion of efficacy (Figure 3).
Deliverability, affordability and sustainability
Deliverability refers to the prospects of an emerging
intervention to overcome environmental and econom-
ical barriers to achieve high coverage, particularly in
low resource settings. This criterion takes into account
the level of difficulty with aerosolized measles vaccine
delivery, the infrastructure and other resources
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ernment capacity and partnership requirements for
achieving near-universal coverage with this new inter-
vention. The aim of MAP (as well as other aerosol
measles vaccine efforts) is also to develop a product
that is primarily suitable for use in low resource envir-
onments, and is capable of quick implementation in
mass campaigns.
Aerosol measles vaccines
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Box-and-Whisker plot of the experts' score
Maximum Burden Reduction of needle-free measles vaccines
Figure 3 The results of Stage II of the CHNRI process – an expert opinion exercise assessing the potential usefulness of investment in
needle-free measles vaccines. CHNRI- Child Health and Nutrition Research Initiative
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The existing subcutaneous measles vaccine is associated
with some safety risks. In the developing world unsafe
needle practices put individuals at the risk of blood
borne viral transmission, including hepatitis C virus
(HCV), hepatitis B virus (HBV) and human immunode-
ficiency virus (HIV) [32]. Unsafe injection practices
comprise needle re-use, inefficient needle sterilization
and improper needle waste disposal. In addition, needle-
stick injuries within the healthcare profession are not
infrequent, carrying an equivalent risk of blood-borne
virus transmission. Approximately 3 million health
workers across the globe are injured by sharps contami-
nated with HBV, HCV or HIV annually [32]. The
Table 1 Summary of major clinical trials on aerosol measles vaccines presented to the expert group for stage II of the
CHNRI process
Reference MV Strain Age group Seroconversion as defined by authors
A.Dilraj et al [46] MV-Schwarz (s/c, aerosol),
MV- Edmonston-Zagreb (s/c,
aerosol)
992
participants
5-14 years
Seroconversion rates (defined as four fold increase in antibody level):
EZ Aerosol – 84.7%
EZ sc – 78.8%
SW Aerosol – 22.7%
SW sc – 62.6%
A.Dilraj et al [47] MV-Schwarz (s/c),
MV- Edmonston-Zagreb (s/c,
aerosol)
337
participants
5-14 years
Seroconversion (defined as four fold increase in antibody level) at 6 years
after revaccination:
EZ Aerosol – 86%
EZ sc – 73%
SW sc – 58%
J.A.Bellanti et al [48] MV- Edmonston-Zagreb (s/c,
aerosol)
49
participants
6-7 years
The mean Specific anti-measles IgG antibody:
EZ sc - 22.9 ± 4.6
EZ aerosol - 53.4 ± 9.4
Results are reported as mean _ µg/ml ± standard error of the mean
J.V.Bennett et al [49] MV-Schwarz (s/c),
MV- Edmonston-Zagreb (s/c,
aerosol)
1624
participants
6-8 years
Change from seronegative to seropositive, >= 120 mIU/ml
EZ aerosol – 65%
EZ sc – 4%
SW sc – 23%
R.M.Wong-Chew et al
[50]
MV- Edmonston-Zagreb (s/c,
aerosol)
114
participants
11-13 months
Seroresponse rates as defined by four fold increase in antibody level:
EZ aerosol – 89.8%
EZ sc – 100%
R.M.Wong-Chew et al
[51]
MV- Edmonston-Zagreb (s/c,
aerosol)
129
participants
8-10 months
Seroresponse rates as defined by four fold increase in antibody level:
EZ Aerosol – 42%
EZ sc – 67%
Table 2 Summary of major pre-clinical trial studies of aerosol measles vaccines presented to the expert group for
stage II of the CHNRI process
Reference Factor for
investigation
Results Comment
Low, N
et al
de Vries
et al
[24,35]
Vaccine strain EZ > Schwarz in all studies. In South Africa, the Schwarz strain was inactivated as an
aerosol.
Laube, B.L
[26]
Device
selection
3 systems for entry at clinical trial: Un-vented, Breath-
enhanced & Ultrasonic nebulizer. All models fulfil safety
and logistic criteria.
Suitability criteria – portable, easy to use, battery-operated,
sanitary, operable with replacement parts.
Coates, A.
L et al[52]
Viral particle
size
Minimum < 10μm
Deep lung deposition <5μm
Size of inhaled droplet is best determinant of lung deposition
Coates, A.
L et al[52]
Number of
infective
particles
<1000 pfu’s; 30-250 pfu’s required to stimulate
immune response
5000 pfu’s delivered in percutaneous measles vaccine
Cohen, B.J
et al[53]
Potency
retention
85-102% vaccine potency retention in all 3 measles
aerosol device’s.
Potential disaggregation of viral particles during aerosolization
accounts for results >100%
de Swart,
R. L et al
[54]
Animal
model –
safety
No superimposed risk in immunocompromised or
asthmatics.
No risk of vaccine-associated encephalitis or Bells palsy
identified.
Concern of illness exacerbation in vulnerable groups.
Postulation of direct CNS contact through cribiform plate
precipitating neurological symptoms.
Higginson et al. BMC Public Health 2011, 11(Suppl 3):S31
http://www.biomedcentral.com/1471-2458/11/S3/S31
Page 8 of 14nebulized device is designed to be easily administered.
This should lower training requirements for individuals
administering the measles vaccine [33]. Consequently,
this should enable a wider span of vaccine delivery, with
the potential to employ non-healthcare staff within rural
communities to distribute and deliver the vaccine. This
would significantly ease pressures on under-staffed
health care systems, such as most of those in the devel-
oping world. The oral polio vaccination campaign is one
good example of such vaccination strategies implemen-
ted using non-medical personnel [34]. Furthermore, this
would reduce the overall cost of the program. However,
a standard dose of aerosolised vaccine is inhaled over 30
seconds with minimal preparation time [35]. Because of
this, an increased health worker contact time is antici-
pated. This may result in lesser number of vaccinations
delivered each day, which could undermine mass vacci-
nation campaigns when very large numbers of children
need to be immunized.
Expanded program on immunization
The new intervention would fit into the current
Expanded Program on Immunization (EPI) schedule.
Guidelines for measles vaccination of infants at 9
months exist in countries with high disease burden for
measles. In countries where measles vaccine uptake is
high, children are routinely immunized between 9 and
12 months [36]. The Working Group on Measles
(WGM) recommends a second measles dose (MCV2) in
countries which achieve over 75% vaccine coverage of
MCV1. SIAs are encouraged every 2-4 years, used as
either follow-up or catch-up programmes, targeting chil-
dren born since the last campaign. They allow for chil-
dren, who have missed their measles vaccination
through the national immunization schedule, to have
another opportunity for vaccination. From 2000 to 2007,
576 million children between 9 months and 14 years of
age were vaccinated against measles through SIAs [4].
Infrastructure
Cold chain has a limited coverage and integrity in devel-
oping countries, resulting in restrictions on vaccine dis-
tribution [37]. The existing measles vaccine is relatively
thermo stable prior to reconstitution [38]. After recon-
s t i t u t i o n ,t h ev a c c i n em u s tb ed i s c a r d e do fw i t h i n6
hours due to risks of potency loss and contamination.
Heat damage occurs through interruptions in the cold
chain or heat shock to the vaccine from the addition of
a warm diluent [38].
The liquid aerosol measles vaccine demands no altera-
tion to the existing measles cold chain requirements.
However, more space may be required to store the
delivery device. Limited storage space is an issue in
many developing countries. The dry powder formulation
proposes to eliminate cold chain requirements. The
potency of the dried vaccine was tested and the results
Current Status
P IV P IV Pre-clinical Phase I P II P III P IV
Liquid aerosol 
measles 
vaccination via 
nebulizer
Liquid aerosol 
measles vaccination 
via inflatable bags 
and valved masks
Figure 4 The current status of the research into measles aerosol vaccines presented to the expert group for stage II of the CHNRI
process
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least eight weeks at 37°C [27]. Cold chain facilities
maintenance costs are approximately $200-300 million
annually [32] and are responsible for almost one third
of the UNICEF’s annual budget for immunization [39].
If research could be directed at producing more vaccines
that did not require cold chain, vast savings could be
made. Additionally, without the limitations of cold
chain, the vaccine could be stored for expansive lengths
of time without degeneration and could be further dis-
tributed to remote areas with no cold chain facilities.
Based on these evidence, the panel of experts expressed
high levels of optimism (score around 80%) regarding
the deliverability of the aerosolized measles vaccine
(Figure 3).
Cost
MAP receives financial and technical support from sev-
eral agencies, most notably the Bill and Melinda Gates
Foundation, the American Red Cross, the WHO and the
US Centers for Disease Control and Prevention. Gener-
ally, measles is a relatively under-funded disease for
Current Status
P IV P IV Pre-clinical Phase I P II P III P IV
Dry-powder measles 
vaccination through 
CAN-BD
Dry-powder 
measles 
vaccination 
through jet-milling
Figure 5 The current status of the research into measles dry powder product presented to the expert group for stage II of the CHNRI
process
Table 3 Summary of studies of dry powder measles product presented to the expert group for stage II of the CHNRI
process
Reference Factor for
investigation
Results Conclusions
LiCalsi, C.,
et al
[55]
Feasibility of dry
powder inhalation
in measles
Optimal vaccine delivery site – lungs; Particle sizing 1-
5μm; Preparation – micronization and jet-milling ;3
Spiros delivery devices designed
Undemonstrable clinical application
de Swart,
R.L., et al
[56]
Dry powder
vaccination in
Macaques
Low seroresponse to measles dry powder blend
compared to injection or liquid aerosol vaccination
Proof of principle evident by stimulation of weak
immune response. Poor device design in macaque
model – loss of vaccine at delivery.
LiCalsi, C.,
et al
[57]
Dry powder
measles vaccine
potency retention
Up to 89% viral potency retention can be achieved with
micronization.
Burger,
J.L., et al
[58]
Stabilizing dry
powder measles
formulations
Myo-inositol> trehalose as a sugar stabilizer in dry
powder measles vaccinations
Myo-inositol is relatively unhygroscopic, improving its
dry powder vaccination credentials
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2009-2010 [4]. The existing measles delivery system is
affordably priced at $0.06 per dose. While the aerosol
device itself is more expensive, savings are expected to
be noticed in the returns gained from diminished blood
borne virus transmission. A recent cost-analysis model
estimated that the societal cost of inappropriate needle
use leading to blood borne virus transmission totals
$26.77 per injection [40]. It is presumed that, based on
this model, there will be cost-savings of an aerosol
device when the wider connotations of the current vac-
cine are factored in. A review assessing the potential
economic impact of introducing a thermo-stable vaccine
in Cambodia, Bangladesh and Ghana predicted its high
cost-effectiveness in all three countries [41]. Savings
would be made through reduced vaccine wastage, the
avoidance of adverse events from unsafe needle practice,
as well as savings from the subtracted cold chain
requirements [32]. Presented with these evidence, the
panel of experts expressed concerns (score around 50%)
over the ability to develop a low-cost aerosolized vac-
cine. However, given the very high level of interest in
the MAP from various funding agencies, the group felt
moderately optimistic (score around 60 percent) regard-
ing possiblity to make the vaccine available at a lower
price to the consumers in developing countries. They
also were moderately optimistic (score around 60 per-
cent) that the production and implementation cost of
the vaccine could be kept low. The low pricing should
also be sustainable, given the high level of commitment
of many donors towards measles elimination pro-
gramme (Figure 3).
Local and context-specific factors
Health systems of all developing nations are not homo-
geneous and therefore cannot be expected to show
exactly the same response in regards to all factors
related to deliverability of any health intervention [42].
Unstable political environment, civil war and natural
disasters are examples of circumstances which can dras-
tically interfere with the distribution of even the most
cost-effective healthcare strategies. Measles control in
the Eastern Mediterranean region has been plagued with
slow progress due to turbulent political climate in a
number of countries [4]. The deliverability factors dis-
cussed here would have their highest index of impact
only if a strong political leadership and commitment
could be generated.
Maximum potential for disease burden reduction
“Disease burden reduction” considers whether there will
be a significant percentage decrease in global measles
mortality (mainly due to the complication of severe
pneumonia) with the introduction of the newly pro-
posed interventions. In 2008, approximately 164,000
individuals died as a consequence of measles despite
considerable efforts to prevent and control disease out-
breaks. Over 90% of these deaths were estimated to
have been in children aged below 5 years [4]. Urbaniza-
tion and rapid population growth pose special chal-
lenges for measles eradication since they facilitate
person-to-person spread o ft h eh i g h l yc o n t a g i o u s
measles virus; experience shows that these conditions
require sustained immunization coverage levels of >95%
to interrupt transmission. The WHO region of Americas
has eliminated measles transmission using the supple-
mentatary immunization activities targeting children
aged 9 months to 14 years to quickly raise immuniza-
tion coverage to ≥95 percent [5]. In 2007, 65% of chil-
dren not receiving their first dose of measles vaccine
came from only 8 countries: India, Nigeria, China,
Ethiopia, Indonesia, Pakistan, the Democratic Republic
of Congo and Bangladesh [7]. This demonstrates that
the barrier to elimination and eradication of measles is
not in the vaccine per se but in its delivery. Hence,
greater investments in either improvement of existing
intervention strategies to increase coverage or identify-
ing new delivery mechanisms are needed [5,43].
A study of vaccination in Mongolia indicated that vac-
cines that reach rural communities suffer increased
breaks in the cold chain, exposing the vaccine to unsui-
table temperatures. Consequentially, rural children
exhibited lower antibody response than urban children
[44]. With the dry powder measles vaccine formulation,
the cold chain requirements can be obviated and there-
fore there is a possibility for even wider immunization
coverage by improved access to marginalised commu-
nities and those residing in remote and hard to reach
areas resulting in greater decline in disease burden.
Based on these evidence and their experience in devel-
oping countries, the panel of experts felt that the aero-
solized measles vaccine would have modest levels of
maximum impact on overall pneumonia disease burden
(median: 5%, interquartile range 1-15%, minimum 0%,
maximum 45%) when compared to the existing measles
vaccine (Figure 3).
Equity
T h ea s s e s s m e n to fav a c c i n ea c c o r d i n gt o“equitability”
takes into account the predicted effects that implemen-
tation of the new technology will have on poor popula-
tions within countries. The score is high when the
experts agree that the resultant impact will reduce
health inequities between rich and poor social groups.
The highest impact of measles mortality is on the poor-
est communities in the world [7]. The aim of introdu-
cing a novel intervention is to target this section of
society in order to decrease health inequities. In Latin
America, measles has been the target of a large scale
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[43]. In a region with very large disparities in economic
wealth, an equitable response to the programme was
achieved by all nations, demonstrating that the “...suc-
cessful implementation of immunization strategies is
more important to achieve elimination than the under-
lying socio-demographic circumstances of the country”
[36].
The greatest uptake of an intervention is amongst the
highest social groups, with the lowest social classes suf-
fering from diminished intervention coverage, weaker
health services and greater disease exposure. This is
l i a b l et oc o n t i n u et ob et h ec a s ef o ra n yn e wi n t e r v e n -
tion which does not aim to tackle the distributive fac-
tors, and which fits the same format as the existing
technologies. In the case of novel interventions, such as
the measles aerosol vaccine, there is the potential to
counteract this monotonous pattern of uptake especially
using SIAs which target the vulnerable and marginalised
communities in developing countries. Disparities in the
coverage of immunization between the rich and poor
are reduced relative to other interventions. This suggests
that investing in immunization as a health strategy is
advantageous as the uptake across the spectrum of
society is close to indifferent and therefore there will be
a reduced gradient of health inequity [45]. The panel
expressed very high levels of optimism (score over 90%)
regarding the ability of the aerosolized measles vaccine
to have a positive impact on equity (Figure 3).
Acceptability to end users
Mothers claimed to prefer the needle-free route in early
measles aerosol clinical trials held in Mexico [11]. Pain
and phobic associations with needle-syringe delivery sys-
tems are the main limiting factors and they result in
reduced compliance with injectable measles vaccine.
Since the attitudes of parents (with regard to injectable
vaccines) are largely similar across the globe, it may not
be incorrect to generalise the results. However, commu-
nity based trials or post licensure field effectiveness
trials will be needed to assess the safety and acceptabil-
ity of aerosol based vaccines more formally. The experts
were very optimistic (score over 80%) that the vaccine
would be acceptable to both the end-users and health
workers (Figure 3).
Discussion
Measles is an important risk factor for childhood pneu-
monia and thus is responsible for a large proportion of
pneumonia associated mortality in young children espe-
cially in low and middle-income countries where the
disease burden due to measles continues to be high.
Although an effective measles vaccine exists, there are
operational challenges concerning the delivery of the
vaccine to achieve universal coverage. The literature
review summarized in this paper presents the evidence
required for making an informed decision on the
research priority that should be given to aerosolized
measles vaccine to reduce the burden of childhood
pneumonia. The scores for the liquid and dry powder
formulations of the inhalable measles vaccine against
the set criteria represent the collective optimism of a
panel of experts drawn from varying technical back-
grounds and affiliations. Although there is currently no
licensed aerosolized measles vaccine, significant progress
is being made for developing one such vaccine.
Intensification of the measles vaccination programme
over the past decade has helped to dramatically reduce
the global disease burden due to measles and thus the
childhood pneumonia mortality. However, the rate of
decline in measles mortality is unlikely to continue at
the same level for long. In order to sustain and enhance
the gains made in reducing the disease burden asso-
ciated with measles, some new approaches are needed.
In Latin America, scaling up of existing vaccination ser-
vices in order to decrease the number of measles cases
across the region has been a very successful strategy [4].
This case of strengthening the investments in existing
vaccination programmes should be acknowledged as a
prospective strategy to be applied in other regions of the
world.
However, investment in novel vaccinations may offer a
promising mode of challenging currently limiting deli-
verability factors. In the case of candidate aerosolized
measles vaccines, the experts expressed low levels of
optimism regarding the criteria of likelihood of efficacy,
l o wc o s to fd e v e l o p m e n ta n dm o d e s ti m p a c to nr e d u -
cing the burden of childhood pneumonia; moderate
levels of optimism regarding answerability, low cost of
production, low cost of implementation and affordabil-
ity; and high levels of optimism regarding deliverability,
sustainability, impact on equity and acceptability to
health workers and end-users. Further research is
needed to establish the safety and optimal age for pri-
mary vaccination using aersolized measles vaccine. The
liquid aerosol vaccination needs to undergo more trials
in children aged less than 5 years as the majority of
immunization successes are demonstrated in older chil-
dren. Efficient post-licensure surveillance systems need
to be put in place to monitor coverage and ensure
reporting of adverse that adverse following immuniza-
tion. For an optimal dry powder measles vaccination
product, it is important that along with assessment of
safety and effectiveness of the vaccine, the maximal
device outputs be calculated before entry into the clini-
cal trial process.
This is the first time such an exercise has been con-
ducted with the aim of predicting the future impact of
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CHNRI methodology was primarily designed to evaluate
existing interventions and competing investment priori-
ties for health research. Even though we used the
CHNRI criteria, we modified it by including systematic
review of available literature and not involving all stake-
holders (e.g. end-users and health workers). The scores
reported in this paper express the collective opinion of a
panel of 20 experts. Although this could be pointed out
as a limitation, the main strengths of this approach are
that it aims to be objective, systematic, evidence based
and explicit.
Conclusions
To summarize, aerosolized measles vaccine presents an
unique opportunity to not only control and eliminate
measles morbidity and mortality in young children, but
also decrease the overall burden of disease due to severe
pneumonia in young children. Although there has been
considerable progress in achieving the vision of effec-
tively delivering measles vaccine through the respiratory
route, it will still be a few years before such a vaccine is
r e a d yt ob ei n c o r p o r a t e di n t ot h er o u t i n eE P Ip r o -
grammes in high disease burden areas.
Additional material
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